Stock 002907 CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chongqing Pharscin Pharmaceutical Co., Ltd.

Equities

002907

CNE100003308

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
13.31 CNY -0.30% Intraday chart for Chongqing Pharscin Pharmaceutical Co., Ltd. +3.98% -13.85%
Apr. 10 Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Apr. 03 Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 7,537 7,537 6,690 5,391 7,250 8,502
Enterprise Value (EV) 1 7,311 7,343 6,430 5,107 6,991 7,999
P/E ratio 61.7 x 54.9 x 39.3 x 45.1 x 78.9 x 83.4 x
Yield 0.38% 0.19% 0.26% 0.21% 0.28% 0.34%
Capitalization / Revenue 12.7 x 10.7 x 7.94 x 6.11 x 8.57 x 10.8 x
EV / Revenue 12.3 x 10.4 x 7.64 x 5.79 x 8.26 x 10.2 x
EV / EBITDA 57 x 48.6 x 33.7 x 32.7 x 42.5 x 46.5 x
EV / FCF 214 x 65.5 x 61.7 x 135 x -2,481 x 4,914 x
FCF Yield 0.47% 1.53% 1.62% 0.74% -0.04% 0.02%
Price to Book 10.5 x 9.09 x 6.25 x 4.56 x 5.73 x 5.28 x
Nbr of stocks (in thousands) 400,060 400,060 401,546 401,701 401,689 417,596
Reference price 2 18.84 18.84 16.66 13.42 18.05 20.36
Announcement Date 4/23/18 3/29/19 4/27/20 4/28/21 4/20/22 4/27/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 592.1 703.4 842.1 882.5 846.1 785.2
EBITDA 1 128.2 151 191.1 155.9 164.5 172
EBIT 1 107.4 129.5 167.6 109.1 94.95 97.59
Operating Margin 18.14% 18.41% 19.9% 12.37% 11.22% 12.43%
Earnings before Tax (EBT) 1 132.4 160.9 198 137 103.4 108.2
Net income 1 112 137.4 169.7 119.2 91.78 98.4
Net margin 18.91% 19.53% 20.16% 13.51% 10.85% 12.53%
EPS 2 0.3054 0.3434 0.4243 0.2973 0.2288 0.2441
Free Cash Flow 1 34.18 112.1 104.1 37.78 -2.817 1.628
FCF margin 5.77% 15.93% 12.37% 4.28% -0.33% 0.21%
FCF Conversion (EBITDA) 26.66% 74.2% 54.51% 24.23% - 0.95%
FCF Conversion (Net income) 30.52% 81.59% 61.35% 31.7% - 1.65%
Dividend per Share 2 0.0710 0.0350 0.0440 0.0280 0.0500 0.0700
Announcement Date 4/23/18 3/29/19 4/27/20 4/28/21 4/20/22 4/27/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 226 195 260 284 259 503
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 34.2 112 104 37.8 -2.82 1.63
ROE (net income / shareholders' equity) 19% 17.7% 17.9% 10.6% 7.5% 6.84%
ROA (Net income/ Total Assets) 8.73% 8.18% 7.67% 4.06% 3.4% 3.35%
Assets 1 1,283 1,680 2,213 2,935 2,701 2,935
Book Value Per Share 2 1.800 2.070 2.670 2.940 3.150 3.860
Cash Flow per Share 2 0.1700 0.6100 0.7100 1.200 1.070 1.210
Capex 1 41.9 36.3 64.7 46.7 56.6 60.6
Capex / Sales 7.07% 5.16% 7.68% 5.29% 6.69% 7.72%
Announcement Date 4/23/18 3/29/19 4/27/20 4/28/21 4/20/22 4/27/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD. Stock Chongqing Pharscin Pharmaceutical Co., Ltd.
-13.85% 767M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002907 Stock
  4. Financials Chongqing Pharscin Pharmaceutical Co., Ltd.